U.S. Mortgage Finance Stock News

NasdaqGS:GLUE
NasdaqGS:GLUEBiotechs

Does Early MRT-2359 Data And Insider Selling Shift The Bull Case For Monte Rosa (GLUE)?

In May 2026, Monte Rosa Therapeutics reported encouraging Phase 1/2 data for MRT-2359 in metastatic castration-resistant prostate cancer and shared new preclinical findings for MRT-55811 showing tumor regression across several cancer models. At the same time, director Anthony M. Manning exercised options and sold US$180,100 of stock, a routine move that contrasts with the company’s recent scientific progress. Next, we’ll examine how these early-stage oncology results, especially the...
NYSE:BOX
NYSE:BOXSoftware

Box Q1 2027 Margin Compression Challenges Bullish Profitability Narratives

Box (BOX) opened Q1 2027 with total revenue of US$305.9 million and basic EPS of US$0.09 on net income of US$11.9 million, setting a measured tone for the new fiscal year. Over the past five reported quarters, revenue has moved from US$276.3 million in Q1 2026 to US$305.9 million in Q1 2027, while basic EPS has ranged from US$0.02 to US$0.48, giving investors a clear view of how the top line and per share earnings have tracked through recent periods. With trailing net profit margins below...
NYSE:OOMA
NYSE:OOMASoftware

Ooma (OOMA) Profitability Turnaround Reinforces Bullish Earnings Growth Narrative

Ooma (OOMA) has kicked off Q1 2027 with revenue of about US$81.1 million and basic EPS of roughly US$0.09, alongside net income of around US$2.6 million. This sets a clear earnings tone for the new fiscal year. The company has seen quarterly revenue move from about US$65.0 million and a small net loss in Q1 2026 to roughly US$81.1 million and a net profit of around US$2.6 million in Q1 2027. Trailing twelve month EPS sits at about US$0.33 on revenue of roughly US$289.7 million, so the latest...
NasdaqGS:API
NasdaqGS:APISoftware

Agora (API) Q1 Profit Holds But Step Down From Q4 Tests Bullish Margin Story

Agora (API) has reported Q1 2026 revenue of US$37.7 million and net income of US$1.1 million, equal to basic EPS of US$0.01, which follows a year where trailing twelve month revenue reached US$145.5 million and EPS came in at US$0.11. Over recent quarters the company has seen revenue move from US$33.3 million in Q1 2025 to US$38.2 million in Q4 2025 and EPS shift from US$0.00 to US$0.05 over the same period, providing a clearer view of how both top line and per share profitability have been...
NasdaqCM:QTTB
NasdaqCM:QTTBBiotechs

Q32 Bio (QTTB) Is Up 126.6% After US$55M Private Placement With Top Healthcare Funds - Has The Bull Case Changed?

Q32 Bio Inc. recently entered into a securities purchase agreement to raise US$55,000,000 through a private placement of 6,725,000 common shares at US$8.00 each and pre-funded warrants for 150,000 shares at US$7.9999, with closing expected on May 28, 2026, subject to customary conditions. The round is led by BVF Partners L.P. with participation from RA Capital Management, OrbiMed, and Atlas Venture, highlighting strong institutional interest in funding Q32 Bio’s development plans. Next,...
NasdaqGS:PONY
NasdaqGS:PONYSoftware

Evaluating Pony AI (PONY) After A Recent Share Price Rebound And Conflicting Valuation Signals

Recent performance and business snapshot Pony AI (PONY) has drawn investor attention after a period where the stock rose 4.3% over the past day and 11.4% over the past week, while declining over the month and past 3 months. At a last close of US$9.74 and a market cap of about US$4.0b, the company is generating revenue of US$110.27m while reporting a net loss of US$141.39m. Reported annual revenue growth of 43.7% sits alongside net income growth of 25.7%. This helps frame how this autonomous...
NYSEAM:ELLO
NYSEAM:ELLORenewable Energy

Ellomay Capital Q1 Loss Worsening Challenges Bullish Narratives Around Premium P/S Valuation

Ellomay Capital (NYSEAM:ELLO) opened 2026 with Q1 revenue of €8.7 million and a loss of €10.7 million in net income, which translated into basic EPS of a €0.78 loss, while trailing 12 month revenue stood at €42.6 million with a €19.7 million net loss and a basic EPS loss of €1.46. Over recent quarters, revenue has moved within a relatively tight band from €8.7 million to €11.3 million, while quarterly EPS has swung between a €0.85 loss and a €0.53 profit, underscoring how earnings are still...
NYSE:SQM
NYSE:SQMChemicals

SQM (NYSE:SQM) Q1 EPS Surge Tests Long Term Earnings Skepticism

Sociedad Química y Minera de Chile (NYSE:SQM) opened 2026 with Q1 revenue of about US$1.8 billion and basic EPS of US$1.28, setting a clear marker for how the year is starting. Over recent quarters, the company has seen revenue move from US$1,073.8 million in Q4 2024 to US$1,036.6 million in Q1 2025, then to US$1,760.0 million in Q1 2026. Over the same period, quarterly basic EPS shifted from US$0.42 to US$0.48 and then to US$1.28, giving investors a concrete view of how the top and bottom...
NYSE:FPS
NYSE:FPSElectrical

Forgent Power Solutions Resets Capital Structure With Equity Raise And Cheaper Debt

Forgent Power Solutions (NYSE:FPS) has launched a major follow on equity offering, aiming to raise fresh capital for the business. The company has also repriced its senior credit facilities, which is expected to materially reduce annual interest expenses. Together, these moves mark a clear shift in Forgent Power Solutions capital structure and financial flexibility. Forgent Power Solutions comes into this financing reset with the stock at $47.3 and strong recent momentum, up 5.7% over the...
OTCPK:WEBC
OTCPK:WEBCMetals and Mining

Webco Industries (OTCPK:WEBC) Net Margin Rebound Challenges Longstanding Bearish Earnings Narratives

Webco Industries (OTCPK:WEBC) has put up a punchy Q3 2026 print, with revenue of US$179.6 million, basic EPS of US$12.28 and trailing 12 month EPS of US$30.18 helping to lift trailing net profit margin to 3.1% from 1.2% a year earlier and earnings up 177.9% over the last year. The company has seen quarterly revenue move from US$155.4 million in Q3 2025 to US$179.6 million in Q3 2026, while quarterly EPS shifted from US$7.54 to US$12.28 over the same period. This sets up a results season in...
NasdaqGS:MLAB
NasdaqGS:MLABLife Sciences

Mesa Laboratories (MLAB) Profit Turnaround Tests Justification For Rich 74x P/E Multiple

Latest FY 2026 earnings snapshot Mesa Laboratories (MLAB) just closed FY 2026 with fourth quarter revenue of US$63.7 million and a loss per share of US$0.75, as net income excluding extra items came in at a loss of US$4.1 million. Over the past year the company has seen quarterly revenue move from US$62.1 million in FY 2025 Q4 to US$63.7 million in FY 2026 Q4, while quarterly EPS has swung between a loss of US$1.31 and a profit of up to US$0.87. This combination of improving trailing...
NYSE:MOV
NYSE:MOVLuxury

Movado Group (MOV) Margin Gain And 80.4% TTM Earnings Growth Test Bullish Narratives

Movado Group (MOV) just posted Q1 2027 results with revenue of US$142.4 million and basic EPS of US$0.30, compared with trailing twelve month revenue of US$681.9 million and EPS of US$1.44 that delivered year-over-year earnings growth of 80.4%. Over the last year, revenue has been broadly steady at 0.4% growth while net profit margin moved from 2.7% to 4.7%. This sets up this quarter as part of a wider shift in the earnings profile. For investors, that margin progression, combined with the...
NYSE:ANF
NYSE:ANFSpecialty Retail

Abercrombie & Fitch (ANF) Margin Decline Tests Bullish Profitability Narratives In Q1 2027

Abercrombie & Fitch (ANF) opened Q1 2027 with revenue of US$1.1b and basic EPS of US$1.49, alongside net income of US$67.1m for the quarter. The company recorded quarterly revenue of US$1.10b in Q1 2026 and US$1.11b in Q1 2027, while basic EPS moved from US$1.63 to US$1.49 over the same period. This presents a picture in which investors are weighing solid top line scale against more mixed per share outcomes. With trailing net margin coming in lower than the prior year in the provided data,...
NasdaqGS:SMTC
NasdaqGS:SMTCSemiconductor

Semtech (SMTC) Turns Q1 EPS Profit Into Test Of Ongoing Turnaround Narratives

Semtech (SMTC) opened Q1 2027 with revenue of about US$291 million, basic EPS of roughly US$0.29 and net income of around US$26.6 million, providing a clear snapshot of its latest quarterly performance. The company reported revenue of about US$251.1 million in Q1 2026 and roughly US$291 million in Q1 2027, while basic EPS moved from about US$0.22 to roughly US$0.29 over the same period. This offers investors a direct view of how the top and bottom line compare year on year. Overall, margins...
NasdaqGS:ASTE
NasdaqGS:ASTEMachinery

Is Astec Industries (ASTE) Fairly Priced After Recent Infrastructure Spending Optimism?

Wondering if Astec Industries at about US$51 per share is offering fair value right now, or if the recent price puts you at risk of overpaying? The stock is up 4.9% over the last 7 days and 14.4% year to date, although it is down 13.1% over the past month, with a 31.0% return over the last year and 44.0% over three years, while the five-year return shows a decline of 20.8%. Recent headlines around infrastructure spending, construction activity and heavy equipment demand have kept attention...
NasdaqGS:PODD
NasdaqGS:PODDMedical Equipment

Insulet Recall Puts Omnipod Reliability And Valuation In Investor Focus

Insulet (NasdaqGS:PODD) issued a voluntary recall and medical device correction for certain Omnipod insulin Pods due to a manufacturing defect that can cause insulin under delivery. The action affects roughly 7 million Pods globally across the Omnipod 5, DASH, and Eros product lines. Insulet has received multiple reports of serious adverse events, including at least 24 severe cases requiring hospitalization, but no fatalities. The company is replacing affected Pods at no cost and does not...
NasdaqCM:CRBP
NasdaqCM:CRBPBiotechs

Corbus Pharmaceuticals (CRBP) Is Down 19.6% After FDA Aligns On CRB-701 Registrational Strategy - Has The Bull Case Changed?

Corbus Pharmaceuticals reported updated Phase 1/2 data for its Nectin-4 antibody‑drug conjugate CRB-701, showing robust activity and manageable safety in HPV‑driven oropharyngeal and cervical cancers, with plans to present the results at the ASCO 2026 meeting and to launch registrational trials in both indications. An interesting development is the FDA’s broad alignment on registrational trial designs targeting accelerated approval in second‑line oropharyngeal squamous cell carcinoma and...
NYSE:D
NYSE:DIntegrated Utilities

Dominion Energy Faces Landmark All Stock Merger And Valuation Question Marks

NextEra Energy and Dominion Energy (NYSE:D) have announced a definitive all stock agreement. The transaction would create the largest utility company in the U.S. if completed. The combined company is expected to operate with dual headquarters and a shared leadership structure. The deal would broaden reach across key power markets serving data centers and electrification trends. Dominion Energy enters this merger process with its shares at $67.2 and a return of 25.8% over the past year,...
NasdaqGS:MNRO
NasdaqGS:MNROSpecialty Retail

Monro (MNRO) Q4 Loss Revives Concerns Over Reliability Of Recent Profit Turnaround

Monro (MNRO) closed FY 2026 with fourth quarter revenue of US$273.8 million and a reported loss of US$6.6 million, equal to EPS of US$0.22, against a trailing twelve month profit of US$2.2 million and EPS of US$0.07 on revenue of US$1.2 billion. Over recent quarters the company has seen revenue move between US$305.8 million in Q3 FY 2025, US$301.0 million in Q1 FY 2026, US$288.9 million in Q2, US$293.4 million in Q3 and US$273.8 million in Q4. EPS has swung from a loss of US$0.72 in Q4 FY...
NYSE:SJM
NYSE:SJMFood

Milk Bone Supergirl Tie Up Tests J M Smucker Growth Story

Milk-Bone, owned by J. M. Smucker, has launched limited-edition Krypto Soft & Chewy Mini Treats. The release is tied to Warner Bros.' upcoming Supergirl film, expanding Milk-Bone's branded collaborations. The partnership is aimed at boosting brand visibility and engaging pet owners through an entertainment tie-in. For investors watching J. M. Smucker (NYSE:SJM), this Milk-Bone and Warner Bros. collaboration adds a fresh marketing angle to the pet treats portfolio. The stock recently closed...
NasdaqGM:APPN
NasdaqGM:APPNSoftware

Is It Time To Reassess Appian (APPN) After This Year’s Share Price Slide?

Wondering whether Appian stock is offering value at its current price, or whether the risks outweigh the potential reward. The share price closed at US$21.64, with a small 1.4% gain over the last week and declines of 1.5% over the last month, 36.5% year to date and 30.7% over the past year. These moves may have shifted how investors view its risk and return profile. These moves sit against a backdrop of ongoing interest in low code and automation platforms. Investors are weighing long term...
NYSE:ABT
NYSE:ABTMedical Equipment

Abbott Clears AI Cardiology And Dual Sensors As Shares Face Pressure

Abbott Laboratories (NYSE:ABT) secured US and European clearance for its Ultreon 3.0 AI-powered coronary imaging platform, aimed at improving decision support during stent placement. The company received CE Mark in Europe for Libre Duo, a dual continuous glucose-ketone sensor designed for more comprehensive diabetes management. Abbott plans to present new evidence on its cancer diagnostics portfolio at the ASCO Annual Meeting, focusing on early detection and treatment guidance. Updated...
NasdaqGS:KC
NasdaqGS:KCIT

Kingsoft Cloud Holdings (NasdaqGS:KC) Q1 Loss Challenges Bullish AI Margin Narratives

Kingsoft Cloud Holdings (NasdaqGS:KC) opened Q1 2026 with revenue of C¥2.7b and a basic EPS loss of C¥1.13. Trailing twelve month figures show revenue of C¥10.3b and a cumulative EPS loss of C¥3.36. Over recent quarters the company has reported revenue of C¥2.2b in Q4 2024, C¥2.0b in Q1 2025 and C¥2.7b in Q1 2026. Quarterly EPS losses ranged from C¥0.80 in Q4 2024 to C¥1.71 in Q2 2025 and C¥1.13 in the latest quarter, highlighting how efficiently revenue may eventually translate into...
NYSE:CPRI
NYSE:CPRILuxury

Capri Holdings (CPRI) Returns To Profitability And Tests Bullish Earnings Growth Narratives

Capri Holdings (CPRI) just wrapped FY 2026 with Q4 revenue of US$796 million and a small loss, with basic EPS coming in at US$0.01, while on a trailing twelve month basis EPS was US$0.66 on revenue of US$3.5 billion. Over the past few quarters, revenue has moved between US$797 million and US$1.0 billion, with quarterly EPS ranging from a loss of US$0.28 to a profit of US$0.48, giving investors a mixed but improving read on profitability. Overall, the latest print points to tight margins and...